Promising Targets of CAR Therapy for Ovarian Cancer
Ovarian cancer, as a common gynecological tumor, is currently recognized as the most lethal gynecological malignancy. Several preclinical experiments and clinical trials have confirmed that adoptive cell immunotherapy using typical CAR-engineered T cells for OC is a promising treatment approach with striking clinical efficacy. The most popular targets for CAR-T cell therapy of ovarian cancer include MSLN,HER2and MUC16.
MSLN is highly expressed in multiple solid tumors, such as ovarian cancer, lung adenocarcinoma, and breast cancer. Considering its low expression on normal mesothelial cells and high expression in ovarian cancer, MSLN is a promising target of CAR T therapy for ovarian cancer.
More than 80% of ovarian cancer is characterized by overexpression of MUC16, and the high expression of MUC16 is an important indicator for the early diagnosis of ovarian cancer. Studies have shown that MUC16-CAR-T cells have specific killing effects on MUC16+ ovarian cancer cells in vitro.
Overexpression and amplification of HER2 is observed in 5-66% of epithelial ovarian cancer, making it an ideal target for ovarian cancer treatment. At present, HER2-specific CAR-T cell therapy has shown good therapeutic potential in the preclinical stage.
Product: FITC-Labeled Human Mesothelin (296-580), His Tag
293 cells were transfected with anti-MSLN-scFv and RFP tag. 2e5 of the cells were stained with FITC-Labeled Human Mesothelin (296-580), His Tag (Cat. No. MSN-HF223, 1 μg/mL) and FITC-labeled protein control. Non-transfected 293 cells and FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-MSLN-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Mesothelin (296-580), His Tag (Cat. No. MSN-HF223).